The Food and Drug Administration (FDA) has recommended that U.S. clinicians and public health professionals temporarily suspend the use of Rotarix (GlaxoSmithKline Biologicals, King of Prussia, Pa.), after porcine circovirus-1 (PCV1) DNA was identified in the rotavirus vaccine.

There is no evidence at this time that PCV1 DNA poses a health risk. The FDA is convening an expert advisory committee on May 7 to learn more about the situation, with further recommendations to follow.

In the meantime, infants should continue to be vaccinated against rotavirus with RotaTeq (Merck & Co. Inc., Whitehouse Station, N.J.).

Rotavirus is the leading cause of severe gastroenteritis in the first five years of life, infecting 80% of children in this age range. One in seven children requires medical assistance, one in 70 is hospitalized and one in 200,000 dies.

Rotarix and RotaTeq are the two vaccines licensed in the United States to prevent severe rotavirus...

You do not currently have access to this content.